193 related articles for article (PubMed ID: 37378942)
21. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
Barceló M; Castells M; Bassas L; Vigués F; Larriba S
Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
[TBL] [Abstract][Full Text] [Related]
22. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions.
Zhang HL; Qin XJ; Cao DL; Zhu Y; Yao XD; Zhang SL; Dai B; Ye DW
Asian J Androl; 2013 Mar; 15(2):231-5. PubMed ID: 23377530
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer.
Bucay N; Sekhon K; Yang T; Majid S; Shahryari V; Hsieh C; Mitsui Y; Deng G; Tabatabai ZL; Yamamura S; Calin GA; Dahiya R; Tanaka Y; Saini S
Oncogene; 2017 May; 36(19):2667-2679. PubMed ID: 27893706
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Value of Prostate-Specific Antigen Combined with Plasma miRNA-149 Expression in Patients with Prostate Cancer Based on Experimental Data and Bioinformatics.
Wang H; Yang L; Mi Y; Wang Y; Ma C; Zhao J; Liu P; Gao Y; Li P
Contrast Media Mol Imaging; 2022; 2022():6094409. PubMed ID: 35935308
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.
Gurbuz V; Kiliccioglu I; Dikmen AU; Bilen CY; Sozen S; Konac E
Gene; 2020 Oct; 758():144963. PubMed ID: 32683077
[TBL] [Abstract][Full Text] [Related]
27. Elevated expression of prostate cancer-associated genes is linked to down-regulation of microRNAs.
Erdmann K; Kaulke K; Thomae C; Huebner D; Sergon M; Froehner M; Wirth MP; Fuessel S
BMC Cancer; 2014 Feb; 14():82. PubMed ID: 24517338
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.
Lin ZY; Huang YQ; Zhang YQ; Han ZD; He HC; Ling XH; Fu X; Dai QS; Cai C; Chen JH; Liang YX; Jiang FN; Zhong WD; Wang F; Wu CL
Int J Cancer; 2014 Aug; 135(3):541-50. PubMed ID: 24382668
[TBL] [Abstract][Full Text] [Related]
29. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification.
Al-Kafaji G; Said HM; Alam MA; Al Naieb ZT
Oncol Lett; 2018 Jul; 16(1):1357-1365. PubMed ID: 30061955
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer.
Yang B; Liu Z; Ning H; Zhang K; Pan D; Ding K; Huang W; Kang XL; Wang Y; Chen X
Cancer Biomark; 2016 Jul; 17(2):223-30. PubMed ID: 27434290
[TBL] [Abstract][Full Text] [Related]
31. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.
Spahn M; Kneitz S; Scholz CJ; Stenger N; Rüdiger T; Ströbel P; Riedmiller H; Kneitz B
Int J Cancer; 2010 Jul; 127(2):394-403. PubMed ID: 19585579
[TBL] [Abstract][Full Text] [Related]
32. Importance of miR-20a expression in prostate cancer tissue.
Pesta M; Klecka J; Kulda V; Topolcan O; Hora M; Eret V; Ludvikova M; Babjuk M; Novak K; Stolz J; Holubec L
Anticancer Res; 2010 Sep; 30(9):3579-83. PubMed ID: 20944140
[TBL] [Abstract][Full Text] [Related]
33. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract][Full Text] [Related]
34. Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.
Lin Y; Chen F; Shen L; Tang X; Du C; Sun Z; Ding H; Chen J; Shen B
J Transl Med; 2018 May; 16(1):134. PubMed ID: 29784056
[TBL] [Abstract][Full Text] [Related]
35. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.
Avgeris M; Stravodimos K; Fragoulis EG; Scorilas A
Br J Cancer; 2013 Jun; 108(12):2573-81. PubMed ID: 23703249
[TBL] [Abstract][Full Text] [Related]
36. Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins.
Tang DG; Li L; Chopra DP; Porter AT
Cancer Res; 1998 Aug; 58(15):3466-79. PubMed ID: 9699682
[TBL] [Abstract][Full Text] [Related]
37. miR-214-5p inhibits human prostate cancer proliferation and migration through regulating CRMP5.
Zheng C; Guo K; Chen B; Wen Y; Xu Y
Cancer Biomark; 2019; 26(2):193-202. PubMed ID: 31403941
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
39. Long non-coding RNA-NEAT1, a sponge for miR-98-5p, promotes expression of oncogene HMGA2 in prostate cancer.
Guo Z; He C; Yang F; Qin L; Lu X; Wu J
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31481527
[TBL] [Abstract][Full Text] [Related]
40. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer.
Byun YJ; Piao XM; Jeong P; Kang HW; Seo SP; Moon SK; Lee JY; Choi YH; Lee HY; Kim WT; Lee SC; Cha EJ; Yun SJ; Kim WJ
Investig Clin Urol; 2021 May; 62(3):340-348. PubMed ID: 33834642
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
